Fate Therapeutics, Inc. FATE R2K

Healthcare · Biotechnology · United States

https://www.fatetherapeutics.com

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Market & Price

Market Cap

$331.03M

Current Price

$2.84

High / Low (52W)

$2.84 / $0.92

Beta

2.14

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$1.55

Price to Book

1.84

P/S

52.41

EV/EBITDA

-1.85

Dividend Yield

Profitability & Returns

ROCE

-52.22%

ROE

-55.50%

ROA

-25.29%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-0.26

EPS (TTM)

$-1.09

Balance Sheet & Liquidity

Debt/Equity

0.43

Quick Ratio

5.75

Current Ratio

5.85

Debt

$76.78M

Total Assets

$318.94M

Current Assets

$208.70M

Working Capital

$172.63M

Ownership

Promoter Holding

1.17%

Chg in Prom Hold

FII / Inst Holding

72.83%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$232.99M

Total Revenue (TTM)

$6.32M

EBITDA

$-125.84M

Free Cash Flow

$-50.07M

Operating Cash Flow

$-103.10M

Shares Outstanding

116.56M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-58.98%

Profit 5Y

17.20%

Revenue (YoY)

-20.30%

Earnings (YoY)

PROS

Profit CAGR of 17.2% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -59.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	FATE Fate Therapeutics, Inc. R2K	2.84	-	$331.03M	-	-52.22%	-55.50%	-58.98%	17.20%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.66M	2.63M	2.82M	2.43M	2.80M	2.52M	5.46M	7.56M	11.14M	13.41M	14.22M	18.41M	18.55M	14.98M	58.98M	933.00K	1.94M	1.93M	6.77M	3.07M	1.63M	1.91M	1.74M	1.37M	1.30M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.91M	38.88M	36.48M	36.09M	34.30M
Operating Income	-7.32M	-7.22M	-6.33M	-	-7.92M	-8.00M	-8.39M	-	-9.97M	-9.57M	-10.34M	-	-14.05M	-19.61M	-16.69M	-	-20.45M	-24.08M	-27.12M	-	-34.49M	-28.71M	-31.49M	-46.21M	-46.78M	-54.62M	-74.47M	-83.11M	-86.39M	-28.59M	-62.56M	-51.28M	-51.07M	-45.08M	-52.38M	-41.28M	-36.97M	-34.73M	-34.72M	-33.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37.95M	-33.69M	-31.51M	-31.66M	-30.08M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37.62M	-34.07M	-32.25M	-32.37M	-31.21M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.88M	-7.78M	-6.89M	-7.45M	-8.38M	-8.41M	-8.74M	-7.94M	-10.13M	-9.64M	-10.68M	-12.50M	-14.13M	-19.65M	-16.78M	-16.03M	-19.76M	-23.48M	-26.61M	-28.30M	-33.52M	-28.07M	-58.68M	-45.09M	-55.13M	-43.31M	-65.69M	-76.11M	-83.56M	-18.88M	-52.76M	-45.17M	-48.00M	-38.43M	-47.68M	-37.62M	-34.07M	-32.25M	-32.37M	-31.21M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.58	-0.45	-0.68	-0.79	-0.86	-0.19	-0.54	-0.46	-0.47	-0.33	-0.40	-0.32	-0.29	-0.27	-0.27	-0.26
R&D Expense	4.57M	4.86M	5.00M	-	6.64M	6.78M	6.80M	-	7.97M	7.93M	8.58M	-	11.48M	16.82M	13.64M	-	17.73M	21.63M	23.20M	-	29.28M	26.67M	30.69M	44.85M	48.02M	53.13M	72.14M	81.31M	79.82M	65.63M	40.88M	34.27M	32.14M	34.60M	34.65M	29.14M	27.43M	25.84M	-	24.70M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	4.40M	4.11M	4.74M	10.68M	31.43M	-	96.30M	63.53M	13.63M	6.65M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	404.69M	254.04M	209.17M	154.35M
Operating Income	-	-	-	-13.29M	-13.56M	-17.68M	-24.90M	-27.78M	-31.96M	-42.12M	-67.09M	-100.73M	-128.09M	-	-308.39M	-190.51M	-195.54M	-147.70M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-294.63M	-172.23M	-176.58M	-134.80M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-281.72M	-160.93M	-186.26M	-136.31M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.17M	-13.33M	-16.22M	-13.43M	-14.24M	-20.89M	-25.88M	-29.99M	-33.46M	-42.95M	-66.60M	-98.15M	-173.39M	-	-281.72M	-160.93M	-186.26M	-136.31M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-2.10	-	-2.91	-1.64	-1.64	-1.15
R&D Expense	-	-	-	9.86M	12.00M	12.01M	16.43M	19.86M	26.45M	34.36M	56.02M	87.77M	125.62M	215.52M	320.45M	172.60M	135.00M	107.83M

Compounded Sales Growth

5 Years:	-58.98%
1 Year:	-20.30%

Compounded Profit Growth

5 Years:	17.20%
1 Year:	-

Stock Price Performance

1 Year:	+134.71%
6 Months:	+167.92%
3 Months:	+91.89%
1 Month:	+129.03%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	11.08M	55.58M	51.18M	67.96M	95.05M	105.29M	213.03M	302.27M	622.46M	-	705.56M	506.22M	440.69M	318.94M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	502.07M	331.54M	291.91M	208.70M
Cash & Equivalents	-	-	-	11.22M	6.39M	9.09M	54.04M	49.10M	64.81M	88.61M	88.95M	190.51M	99.81M	167.35M	-	61.33M	41.87M	36.06M	46.63M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.48M	1.83M	3.54M	916.00K
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	221.62M	137.80M	121.97M	111.75M
Current Liabilities	-	-	-	-	-	4.85M	4.60M	4.57M	13.44M	15.19M	11.05M	27.26M	27.81M	85.56M	-	114.05M	39.09M	38.52M	36.07M
Long Term Debt	-	-	-	-	-	1.73M	-	18.07M	10.69M	2.50M	14.81M	12.45M	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109.34M	103.54M	85.27M	77.85M
Total Equity	-1.22M	-8.35M	-21.46M	-37.44M	-50.68M	-52.83M	50.85M	28.34M	38.04M	73.15M	77.19M	160.47M	244.76M	384.44M	-	483.94M	368.42M	318.73M	207.18M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.29M	98.63M	113.93M	115.36M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-29.82M	-36.82M	-38.65M	-83.17M	-39.23M	-	-248.21M	-132.26M	-122.87M	-106.08M
Investing Cash Flow	-	-	-	-	-	-4.11M	-10.20M	-463.00K	-157.45M	-161.08M	-	166.75M	112.67M	12.22M	111.17M
Financing Cash Flow	-	-	-	-	-	57.74M	47.36M	140.78M	149.93M	282.84M	-	9.21M	85.00K	99.89M	5.49M
Capital Expenditure	-2.00K	-709.00K	-244.00K	-882.00K	-1.50M	-457.00K	-1.73M	-2.30M	-7.39M	-4.93M	-	-35.57M	-6.15M	-730.00K	-5.95M
Free Cash Flow	-	-	-	-	-	-30.28M	-38.54M	-40.95M	-90.57M	-44.16M	-	-283.77M	-138.42M	-123.60M	-112.04M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-72.25M	-19.51M	-10.76M	10.57M
Share Buybacks	7.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-726.1%	-1,025.9%	-1,415.4%	-943.1%	-407.5%	-	-320.2%	-299.9%	-1,434.5%	-2,222.4%
Net Margin %	-	-	-	-	-	-	-	-	-760.2%	-1,046.1%	-1,405.0%	-919.0%	-551.6%	-	-292.5%	-253.3%	-1,366.5%	-2,051.1%
ROE %	85.8%	62.1%	43.3%	26.5%	27.0%	-41.1%	-91.3%	-78.8%	-45.7%	-55.6%	-41.5%	-40.1%	-45.1%	-	-58.2%	-43.7%	-58.4%	-65.8%
ROCE %	-	-	-	-	-217.7%	-34.7%	-53.4%	-51.0%	-40.0%	-44.7%	-36.1%	-36.7%	-23.9%	-	-52.1%	-40.8%	-48.6%	-52.2%

Shareholding Pattern

Insiders

1.17%

Institutions

72.83%

Public Float

73.69%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Redmile Group, LLC	11.04%	12.87M	$36.56M
2	Blackrock Inc.	8.64%	10.07M	$28.59M
3	Vanguard Capital Management LLC	3.60%	4.19M	$11.91M
4	Vanguard Portfolio Management LLC	3.55%	4.13M	$11.74M
5	Acadian Asset Management. LLC	3.53%	4.12M	$11.70M
6	Two Sigma Investments, LP	2.97%	3.47M	$9.85M
7	Johnson & Johnson	2.90%	3.38M	$9.60M
8	AQR Capital Management, LLC	2.58%	3.00M	$8.52M
9	Renaissance Technologies, LLC	2.55%	2.97M	$8.45M
10	Geode Capital Management, LLC	2.22%	2.59M	$7.36M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FATE

No recent headlines available.

FATE · Healthcare